Kalshi and AppliedXL Launch Markets to Make Drug Development Odds Public for the First Time

Kalshi and AppliedXL announced a partnership to launch pilot prediction markets that will make the probabilities of drug development successes publicly viewable. This initiative aims to solve the problem of proprietary data that has long kept drug success odds hidden from the public and investors. The new markets allow participants to place wagers on specific clinical trial outcomes and FDA regulatory decisions. The platform ensures that contract resolutions rely only on independent public records, such as registered primary endpoints or official FDA approval letters, rather than on favorable company statements. AppliedXL, the public intelligence company, built the necessary infrastructure to verify these public records, ensuring transparency and making the data auditable. This provides investors with a measurable metric that reflects evidence, allowing individuals who were not involved in drug development to accurately assess the risks involved. To maintain integrity, the initial pilot markets are limited to late-stage trials, and Kalshi requires employment verification for all traders. The effort marks a significant step toward bringing objective financial data to an industry previously characterized by opaque internal estimates.

Sources